All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CT-868
Therapeutic Area: Endocrinology Product Name: CT-868
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 30, 2020
Details:
The funding will support initiation early in 2021 of a 26-week dose ranging phase 2 study for CT-868 and phase 1-2 studies for CT-388 and involve more than 300 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZT-01
Therapeutic Area: Endocrinology Product Name: ZT-01
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The study employs a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) trial design and will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT-01.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antiaging Glycopeptide
Therapeutic Area: Endocrinology Product Name: PKX-001
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
This phase of the clinical trials, based on safety data received from the initial studies in Phase 1, demonstrated the safety of the molecule and are now approved to adjust the protocols for optimal efficacy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): O304-Na,Dapagliflozin
Therapeutic Area: Endocrinology Product Name: O304-Na
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antiaging Glycopeptide
Therapeutic Area: Endocrinology Product Name: PKX-001
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Upon approval from Health Canada and upon final approval by the University of Alberta ethics committee, the Company will be immediately delivering over 75-grams of the PKX-001 to the University to accommodate the ongoing clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMT-002
Therapeutic Area: Endocrinology Product Name: IMT-002
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
The trial is designed as a single ascending dose (SAD) Phase 1a study of healthy subjects to demonstrate drug safety and tolerability.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The presesntation will highlight data from company's Phase I study investigating the PD, PK and safety of AT247 in comparison with NovoRapid® and Fiasp.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dorzagliatin,Empagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
Details:
The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NP-500
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Atlas Sciences
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
Details:
Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antiaging Glycopeptide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
The PKX-001 study will treat islet cells prior to transplantation into human test subjects. The clinical trials primary objective is the establishment of patient safety.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
